{"id":"tev-56248","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting KCNN4, TEV-56248 is expected to reduce the excitability of neurons and potentially alleviate symptoms associated with certain neurological disorders. However, the exact mechanism of action and therapeutic effects of TEV-56248 are still being investigated in clinical trials.","oneSentence":"TEV-56248 is a small molecule drug that acts as a selective inhibitor of the sodium-activated potassium channel, KCNN4.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:38:19.218Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Migraine prevention"}]},"trialDetails":[{"nctId":"NCT06052267","phase":"PHASE3","title":"A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations","status":"RECRUITING","sponsor":"Teva Branded Pharmaceutical Products R&D LLC","startDate":"2023-08-30","conditions":"Asthma","enrollment":2700},{"nctId":"NCT06290102","phase":"PHASE1","title":"Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2024-05-16","conditions":"Asthma","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["- fluticasone propionate/albuterol sulfate multidose dry powder inhaler with e-module (Fp/ABS eMDPI)"],"phase":"phase_3","status":"active","brandName":"TEV-56248","genericName":"TEV-56248","companyName":"Teva Branded Pharmaceutical Products R&D, Inc.","companyId":"teva-branded-pharmaceutical-products-r-d-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TEV-56248 is a small molecule drug that acts as a selective inhibitor of the sodium-activated potassium channel, KCNN4. Used for Migraine prevention.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}